Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Pharma Frontiers
8 min read
CD19 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
A visual CD19 target evaluation report for B-ALL, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.
Pharma Frontiers
8 min read
BCMA Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
A visual BCMA target evaluation report for multiple myeloma, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.
Pharma Pioneer
8 min read
DLL3 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
A visual DLL3 target evaluation report for SCLC, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.
Pharma Pioneer
8 min read
Nectin-4 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
A visual Nectin-4 target evaluation report for urothelial carcinoma, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.
Hot Spotlight
8 min read
MSLN Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
A visual MSLN target evaluation report for ovarian cancer, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.
Hot Spotlight
8 min read
B7-H3 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
A visual B7-H3 target evaluation report for NSCLC, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.
8 min read
TROP2 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
A visual TROP2 target evaluation report for breast cancer, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.
8 min read
CLDN18.2 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
A visual CLDN18.2 target evaluation report for gastric cancer, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.
8 min read
LAG3 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
A visual LAG3 target evaluation report for melanoma, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.
8 min read
TIGIT Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
A visual TIGIT target evaluation report for NSCLC, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.
8 min read
CTLA4 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
A visual CTLA4 target evaluation report for melanoma, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.
8 min read
PD-L1 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
9 July 2026
A visual PD-L1 target evaluation report for NSCLC, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.